David Schreiber is President and Chief Executive Officer. Schreiber brings more than two decades of executive management experience in the healthcare industry to Atherotech. Prior to Atherotech, Shreiber spent seven years at Dianon Systems, Inc. as a senior vice president and chief financial officer and also served on the Board of Specialty Labs driving the turnaround that led to the successful sale of the company to Welsh Carson. Before Dianon, Schreiber spent 11 years at Quest Diagnostics, ending his tenure there as vice president and general manager of the company’s Midwest region. Schreiber earned a B.S. degree in finance and an MBA from Northern Illinois University. He currently serves on the board of Nanogen, Inc. (Nasdaq: NGEN), a medical diagnostics company.

Kneeland Youngblood, M.D., is Chairman of the Board. Youngblood has extensive investment experience, having served from 1993 to 1999 on the board of the $100 billion Teacher Retirement system of Texas (TRS). In his capacity as a trustee, he was actively involved in hiring investment advisors, determining asset allocations and formulating investment/benefit policies. He served as chairman of the Fund's Real Estate Committee, where he directed a major restructuring of the $1.4 billion portfolio. He also served on the Board of Directors and developed direct private equity experience with the Texas Growth Fund, a $500 million private equity fund providing growth and expansion capital. Mr. Youngblood is also a Chairman of the board of the American Beacon Funds, a $20 billion investment affiliate of American Airlines. Mr. Youngblood's other board memberships include: Burger King, Starwood Hotels and Resorts and the City of Dallas Employee Retirement System. He is also a Director Emeritus of iStar Financial, a NYSE publicly traded REIT, and a Director Emeritus of the U.S. Enrichment Corporation. Mr. Youngblood is a founder of Pharos Capital Group. He is a graduate of Princeton University and the University of Texas Southwestern Medical School, and is a member of the Council on Foreign Relations.

Michael V. Mullen is Chief Financial Officer. Mullen is an experienced accounting and finance executive who also brings perspective gained from a unique background combining accounting and laboratory sciences. Mullen most recently served as chief financial officer for Child Development Schools, Inc., a retail provider of preschools and early care centers in the Southeast, during a time in which double-digit annual revenue and cash flow growth was achieved, ultimately leading to a sell transaction to private equity. Previously, he served as the controller at Atherotech, where he managed the accounting, reimbursement, and accounts payable departments. Mullen also was an audit manager with a Big Four Accounting Firm-Ernst & Young, LLP. He earned an equivalent bachelor’s degree in accounting from the University of Alabama at Birmingham and a bachelor’s degree in laboratory science from Auburn University. Mullen is a member of the Alabama Society of Certified Public Accountants and the American Institute of Certified Public Accounts.

Kevin Anders is Vice President of Sales and Marketing. Anders is an experienced healthcare sales executive with more than two decades of experience in the healthcare industry. Prior to joining Atherotech, Anders most recently served as a regional business development executive at Laboratory Corporation of America where he worked with hospitals, pathology groups and physician laboratories. Previously, he spent 10 years at Quest Diagnostics in sales management positions.

James Ehrlich, M.D., is Chief Medical Officer. Ehrlich brings over 30 years of clinical healthcare experience as a veteran in the development of advanced coronary risk assessment services and technology. His recent experience consists of serving as the Medical Director of several coronary risk assessment and prevention facilities, as well as the head of the medical advisory board of U.S. Preventive Medicine. Ehrlich also serves on the clinical faculty of two medical schools, the University of Colorado Health Sciences Center (endocrine division) and the George Washington University Medical Center (department of medicine). His research and publications have focused primarily on the early identification and monitoring of sub-clinical atherosclerosis in insulin-resistant states. Ehrlich also directs physician seminars on preventive medicine worldwide. Ehrlich is on the cardiovascular advisory panels for Pfizer and Genzyme and speaks on behalf of numerous diagnostic and pharmaceutical corporations. Ehrlich received his degree in Medicine from Boston University in 1976 (magna cum laude).

Bob Shufflebarger is Vice President of Operations. Shufflebarger has worked with early stage technology companies for most of his career. He has been at Atherotech since 2000 where he led the scale-up of VAP testing operations. Prior to Atherotech he managed marketing and business development activities for Southern Research Institute, a contract research organization in Birmingham. After college he worked seven years with two privately held specialty chemical manufacturers as a chemist and quality control manager before returning to school to pursue a business degree. Shufflebarger earned a B.S. degree in Chemistry from Birmingham-Southern College and an MBA from Duke University.